You are here > News and publications

News and publications

Promethera Biosciences opens the French part of its phase I/II clinical trial in cell therapy


Promethera successfully administers Promethera® HepaStem in an adolescent suffering from an Urea Cycle Disorder at Hôpital Jeanne de Flandre (Lille, France)


Mont-Saint-Guibert (Belgium) - February 27, 2013 – Promethera Biosciences, a Belgian biotechnology company developing Promethera®HepaStem, a cell-based therapy for the treatment of liver-based metabolic diseases including Crigler-Najjar Syndrome and Urea Cycle Disorders, announces today that it has successfully treated a patient with liver progenitor cells enrolled in its Phase I/II trial. The intervention was performed in January 2013 at the University Children’s Hospital Jeanne de Flandre in Lille (France). 



Download this file (EN)


Télécharger ce fichier (FR)


PROMETHERA Biosciences S.A./N.V.
Watson & Crick Hill
Rue Granbonpré, 11
B-1435 Mont-Saint-Guibert
Tél.: +32 (0)10 39 43 00
Fax: +32 (0)10 39 43 01